Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

China approves first domestically produced nine-valent HPV vaccine

Xinhua | Updated: 2025-05-30 16:14
Share
Share - WeChat

XIAMEN -- China approved its first domestically developed nine-valent human papillomavirus (HPV) vaccine on Thursday, according to the National Medical Products Administration.

The vaccine, Cecolin 9, was jointly developed by the Xiang An Biomedicine Laboratory, Xiamen University and Wantai BioPharm. Its approval makes China the second country in the world — after the United States — with the capability to independently supply high-valency HPV vaccines.

Since 2019, the vaccine has been through five clinical trials conducted across China, involving more than 11,000 healthy volunteers aged nine to 45.

Results from these trials showed that the vaccine provides strong protection against HPV types 16 and 18 — the same strains covered by the two-valent vaccine — as well as five other HPV types 31, 33, 45, 52 and 58, with a protection rate of over 98 percent against persistent infections lasting more than 12 months and a 100 percent protection rate against cervical infections.

For girls aged nine to 17, just two doses are sufficient to produce an immune response comparable to that seen in women aged 18 to 26 who receive three doses. For girls aged 15 to 17, it is currently the only two-dose HPV vaccine available in China.

A comparative study showed that the new vaccine offers immune responses comparable with similar international products for at least 30 months after full immunization. These findings have been published in The Lancet Infectious Diseases.

The new vaccine is the latest achievement from the research team that also developed China's first domestically made two-valent HPV vaccine in 2019. In 2021, the two-valent HPV vaccine received prequalification from the World Health Organization (WHO) and has since entered the markets of 21 countries.

Cervical cancer was the fourth most common cancer among women worldwide in 2022, according to the WHO. China made free HPV vaccination accessible to approximately 40 percent of girls aged 13 to 14 in 2024, as part of its ongoing work to tackle cervical cancer, according to the National Health Commission.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 99久久精品费精品国产| 亚洲av无码欧洲av无码网站| 色国产精品一区在线观看| 国产韩国精品一区二区三区| 中文字幕曰产乱码| 欧美国产人妖另类色视频| 制服丝袜第六页| 高h视频在线观看| 国产美女牲交视频| 一本色道久久综合狠狠躁篇| 日韩毛片基地一区二区三区| 亚洲男人天堂2022| 精品无码综合一区二区三区| 国产成a人亚洲精v品无码| 91香蕉视频黄| 性生活大片免费看| 久久精品国产99国产精品| 欧美老少配xxxxx| 冠希实干阿娇13分钟视频在线看| 香蕉成人伊视频在线观看| 国产精品美女久久久久久2018| 一区二区三区免费视频观看| 日本卡一卡2卡三卡4卡无卡| 亚洲一区二区在线视频| 爱情鸟第一论坛com高清免费| 啊昂…啊昂高h| 麻麻张开腿让我爽了一夜黄文| 国产精品高清久久久久久久| 一个人看的片免费高清大全| 日本乱子伦xxxx| 亚洲av人无码综合在线观看| 欲乱美女诗涵番外5| 免费黄色a级片| 色八a级在线观看| 国产成a人片在线观看视频下载| 1313午夜精品久久午夜片| 夜夜爽77777妓女免费看| 三个黑人上我一个经过| 日韩三级电影院| 亚洲专区一路线二| 欧美视频在线观看免费最新|